All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ABNCoV2
Therapeutic Area: Infections and Infectious Diseases Product Name: ABNCoV2
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Radhoud University Medical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
Details:
The latest data confirm the previous strong immunogenicity results already published, and further demonstrate a protective efficacy of ABNCoV2 post-challenge with SARS-CoV-2.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Niclosamide
Therapeutic Area: Infections and Infectious Diseases Product Name: UNI911
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
UNION has successfully completed inhalation dosing of 44 healthy volunteers, confirming the safety and tolerability of UNI911. UNI911 utilizes an optimized salt form of niclosamide, an existing potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Niclosamide
Therapeutic Area: Infections and Infectious Diseases Product Name: UNI911
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
Details:
Danish Medicines Agency has approved initiation of a clinical study with an optimized salt form of niclosamide as a new treatment candidate for COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MVA-BN-WEV
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2020
Details:
Data from the study showed that the vaccine was well tolerated and immunogenic across all dose groups.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
